Case acceptance · 2026-08-06
A quarter of UK adults delay dental treatment because of cost. What the research says about monthly price framing, and how to present finance so more plans get accepted.
Two patients sit through the same consultation, see the same treatment plan, and hear the same clinical case for going ahead. One is quoted "£3,000". The other is quoted "from £89 a month". Only one of those numbers has to fight the mortgage, the car and the holiday for space in this month's budget.
The treatment is identical. The total cost can be identical. But the decision the patient is being asked to make is completely different, and that difference shows up directly in your case acceptance rate.
This isn't a hunch about patient psychology. It's the most consistently documented barrier in UK dentistry.
The most recent Adult Oral Health Survey, the large-scale national survey of adult dental health in England, found that a quarter (25%) of adults had delayed dental care or treatment because of the cost, and a third (33%) said cost had affected the type of care or treatment they received. They didn't necessarily refuse treatment outright; they downgraded it, deferred it, or quietly let it lapse.
The General Dental Council's 2022 survey of the UK public found the same pattern from the other direction: nearly a quarter of people avoided seeing a dental professional at all due to concerns about cost, with those squeezed hardest by the cost of living cutting back on dental care first.
So when a patient hears "£3,000" and says "I'll think about it", the honest translation is usually not "I need to reflect on the clinical merits". It's "I can't see where that lump sum comes from", said politely, on the way out.
The behavioural research here is decades old and remarkably robust. In a landmark Journal of Consumer Research paper, Harvard's John Gourville showed that reframing an aggregate cost as a small recurring amount, the "pennies-a-day" strategy, systematically increases willingness to go ahead, even when the total amount paid is exactly the same.
The mechanism matters for how you use it. A lump sum gets mentally compared against other lump sums, and for most households, £3,000 lands in the same category as "new boiler" or "family holiday": rare, painful, deferrable. A monthly amount gets compared against other monthly amounts, the gym, the phone contract, the streaming subscriptions. £89 a month sits comfortably in that second list. Same money, different mental competition.
Follow-up research in the Journal of Consumer Psychology on temporally framed prices confirms the framing choice itself, "£89 per month" versus "£1,068 per year", materially changes how consumers evaluate the same offer.
Dentistry is close to a textbook application: high-value, plannable treatment, quoted to patients who overwhelmingly budget monthly.
Most private practices in the UK already have patient finance available. Far fewer get case-acceptance value from it, because of how it's presented:
Quote both numbers, every time. For any plan above a few hundred pounds, the monthly figure should appear alongside the total, in the consultation, on the printed or digital plan, and in every follow-up. "£3,000, or from £89 a month" is a different proposition from "£3,000".
Present it in the chair, at the moment of decision. The point of maximum motivation is right after the patient has understood the clinical case. That's when the affordability question is answered, not at reception, not in a call-back.
Use soft-search eligibility checks. Modern, regulated patient finance can check eligibility with a soft search that doesn't affect the patient's credit score, with a decision in under a minute. That removes the other silent objection, "what if I apply and get declined?", before it forms.
Put the monthly figure in your follow-ups. Deferred plans should be followed up on a structured cadence, and every touch should lead with the monthly framing. A patient who ignored "£3,000" two weeks ago may respond to "from £89 a month" today. It's a genuinely different offer to their household budget.
Track acceptance by payment type. Split your case acceptance rate by lump-sum vs financed plans. If financed plans are accepted at a materially higher rate, the typical pattern, that's your evidence for making the monthly presentation standard rather than optional. (If you don't yet know your baseline, start with our UK case acceptance benchmarks.)
Take a practice presenting £40,000 of private treatment plans a month at a 40% acceptance rate: £16,000 accepted. If systematic monthly-first presentation moves acceptance to 50%, well within the range practices see when finance goes from "available on request" to "presented by default", that's £20,000 accepted from the same consultations, the same diagnoses and the same chair time. £4,000 a month, £48,000 a year, with no additional marketing spend.
And unlike a new patient campaign, the cost is close to zero: the patients are already in the chair, the treatment is already diagnosed, and well-structured finance options can carry no cost to the clinic.
The patients who most need this are the 25% who delay for cost reasons, people who want the treatment and have been given no realistic way to say yes. Monthly pricing isn't a sales trick. It's removing an artificial barrier between a patient and treatment they've already decided they want.
Want to see how your practice presents treatment costs today, and what a monthly-first approach would change? Request a free discovery report and we'll map it against your current case acceptance numbers.